Tepnel Completes Acquisition of Orchid's Diagnostics Unit

22-Jan-2004

PRINCETON, N.J., and MANCHESTER, England - Orchid BioSciences, Inc. and Tepnel Life Sciences PLC announced that Tepnel has completed its acquisition of certain assets and liabilities of Orchid's diagnostics unit. The diagnostics unit, which will now operate as Tepnel Lifecodes Corporation in the U.S. and Tepnel Diagnostics Ltd. in Europe, provides systems, consumables and services for HLA testing for organ transplantation, and genetic screening for disease predisposition, as well as certain related support services.

Under the terms of the agreement, Tepnel has acquired the product and services business of Orchid Diagnostics unit in the U.S., the U.K. and Belgium, including its LifeMatch(TM) system and consumable product line for HLA testing and its Elucigene(TM) product line for testing of certain genetic diseases, as well as certain liabilities of the diagnostics business.

Tepnel has taken control f the facilities formerly occupied by Orchid's diagnostic unit in Stamford, Connecticut and Brussels, Belgium, and has indicated its intention to retain all of the diagnostics unit's employees.

Other news from the department

Most read news

More news from our other portals

Under the magnifying glass: The world of microscopy

See the theme worlds for related content

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper
View topic world

Topic world Diagnostics

Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.

1 whitepaper